Genetics
A rapid NdeI-based PCR screen finds the intron 14 CETP splicing defect in 21 of 121 Japanese patients with hyperalphalipoproteinemia (Hum Genet 1993)
Original title: Rapid detection and prevalence of cholesteryl ester transfer protein deficiency caused by an intron 14 splicing defect in hyperalphalipoproteinemia
A rapid polymerase chain reaction (PCR)-based screening method that creates a novel NdeI restriction site in mutant alleles was used to detect the intron 14 G to A splicing defect of the cholesteryl ester transfer protein (CETP) gene, a common cause of Japanese hyperalphalipoproteinemia. Among 121 unrelated hyperalphalipoproteinemic subjects with HDL cholesterol of 60 mg/dl (1.55 mmol/l) or greater, 21 carried the mutation, including 8 homozygotes. Allele frequency rose with HDL cholesterol level: 1.5% (1/68), 2.8% (2/72), 7.1% (4/56), and 47.8% (22/46) in the 60-79, 80-99, 100-119, and 120 mg/dl or greater strata, respectively. Based on the population distribution of HDL cholesterol, the frequency of the mutant allele in the general population was estimated at 0.81%.
Original abstract
A deficiency of plasma cholesteryl ester transfer protein (CETP) is one of the genetic causes of increased serum high density lipoprotein (HDL)-cholesterol levels (hyperalphalipoproteinemia). A splicing defect (G-->A mutation) at the +1 position of intron 14 of the human CETP gene is a common mutation in the Japanese CETP deficiency. A rapid screening method for the splicing defect by means of primer-specified restriction map modification was described. The frequency of the mutation in hyperalphalipoproteinemia was determined, and its frequency in the general population was estimated. During polymerase chain reaction (PCR) with a modified primer, a novel NdeI restriction endonuclease site was created from the mutated allele in the PCR products, which could be visualized after electrophoresis of the digested products. As a result, 21 of 121 unrelated hyperalphalipoproteinemic subjects with HDL-cholesterol > or = 60 mg/dl (1.55 mmol/l), were found to have the G-->A mutation. Of the 21 individuals, 8 were found to be homozygous for the mutation. Allele frequency of the mutation was 1.5% (1/68), 2.8% (2/72), 7.1% (4/56), and 47.8% (22/46) in the groups with HDL-cholesterol levels of 60-79 mg/dl, 80-99 mg/dl, 100-119 mg/dl, and > or = 120 mg/dl, respectively. Based on the percentage of the area under the computed normal distribution curve of serum HDL-cholesterol, the frequency of the mutated allele in the general population was estimated to be 0.81% from the present results. This rapid detection method facilitates large-scale screening of CETP deficiency caused by the splicing defect. The mutation was frequent in Japanese subjects with hyperalphalipoproteinemia, especially in the group with HDL-cholesterol > or = 120 mg/dl.
Summary written by cetpinhibition.org from the published abstract; figures as published. Page updated 19 August 2026. Methods.